vs
Side-by-side financial comparison of Dolby Laboratories, Inc. (DLB) and Metallus Inc. (MTUS). Click either name above to swap in a different company.
Dolby Laboratories, Inc. is the larger business by last-quarter revenue ($395.6M vs $308.3M, roughly 1.3× Metallus Inc.). Dolby Laboratories, Inc. runs the higher net margin — 24.0% vs 1.8%, a 22.2% gap on every dollar of revenue. On growth, Metallus Inc. posted the faster year-over-year revenue change (9.9% vs 7.1%). Over the past eight quarters, Dolby Laboratories, Inc.'s revenue compounded faster (13.9% CAGR vs 2.3%).
Dolby Laboratories, Inc. is an American technology corporation specializing in audio noise reduction, audio encoding/compression, spatial audio, and high-dynamic-range television (HDR) imaging. Dolby licenses its technologies to consumer electronics manufacturers.
DLB vs MTUS — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $395.6M | $308.3M |
| Net Profit | $94.9M | $5.4M |
| Gross Margin | 88.7% | 8.1% |
| Operating Margin | 28.5% | — |
| Net Margin | 24.0% | 1.8% |
| Revenue YoY | 7.1% | 9.9% |
| Net Profit YoY | 3.4% | 315.4% |
| EPS (diluted) | $0.99 | $0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | $395.6M | — | ||
| Q1 26 | $346.7M | $308.3M | ||
| Q4 25 | $346.7M | $267.3M | ||
| Q3 25 | $307.0M | $305.9M | ||
| Q2 25 | $315.5M | $304.6M | ||
| Q1 25 | $369.6M | $280.5M | ||
| Q4 24 | $357.0M | $240.5M | ||
| Q3 24 | $304.8M | $227.2M |
| Q2 26 | $94.9M | — | ||
| Q1 26 | $53.3M | $5.4M | ||
| Q4 25 | $53.3M | $-14.3M | ||
| Q3 25 | $49.3M | $8.1M | ||
| Q2 25 | $46.1M | $3.7M | ||
| Q1 25 | $91.8M | $1.3M | ||
| Q4 24 | $67.8M | $-21.4M | ||
| Q3 24 | $58.6M | $-5.9M |
| Q2 26 | 88.7% | — | ||
| Q1 26 | 87.5% | 8.1% | ||
| Q4 25 | 87.5% | 2.2% | ||
| Q3 25 | 87.1% | 11.4% | ||
| Q2 25 | 86.1% | 10.6% | ||
| Q1 25 | 90.3% | 7.8% | ||
| Q4 24 | 88.6% | 4.5% | ||
| Q3 24 | 88.8% | 5.3% |
| Q2 26 | 28.5% | — | ||
| Q1 26 | 17.9% | — | ||
| Q4 25 | 17.9% | -7.7% | ||
| Q3 25 | 9.7% | 3.6% | ||
| Q2 25 | 15.1% | 2.8% | ||
| Q1 25 | 29.2% | 1.0% | ||
| Q4 24 | 22.4% | -10.1% | ||
| Q3 24 | 15.2% | -3.1% |
| Q2 26 | 24.0% | — | ||
| Q1 26 | 15.4% | 1.8% | ||
| Q4 25 | 15.4% | -5.3% | ||
| Q3 25 | 16.1% | 2.6% | ||
| Q2 25 | 14.6% | 1.2% | ||
| Q1 25 | 24.8% | 0.5% | ||
| Q4 24 | 19.0% | -8.9% | ||
| Q3 24 | 19.2% | -2.6% |
| Q2 26 | $0.99 | — | ||
| Q1 26 | $0.55 | $0.13 | ||
| Q4 25 | $0.55 | $-0.34 | ||
| Q3 25 | $0.50 | $0.19 | ||
| Q2 25 | $0.48 | $0.09 | ||
| Q1 25 | $0.94 | $0.03 | ||
| Q4 24 | $0.70 | $-0.46 | ||
| Q3 24 | $0.59 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $594.7M | $104.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.6B | $683.0M |
| Total Assets | $3.2B | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $594.7M | — | ||
| Q1 26 | $644.6M | $104.0M | ||
| Q4 25 | $644.6M | $156.7M | ||
| Q3 25 | $702.6M | $191.5M | ||
| Q2 25 | $699.3M | $190.8M | ||
| Q1 25 | $626.6M | $180.3M | ||
| Q4 24 | $520.8M | $240.7M | ||
| Q3 24 | $482.0M | $254.6M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $5.4M | ||
| Q4 24 | — | $5.4M | ||
| Q3 24 | — | $13.2M |
| Q2 26 | $2.6B | — | ||
| Q1 26 | $2.6B | $683.0M | ||
| Q4 25 | $2.6B | $686.0M | ||
| Q3 25 | $2.6B | $697.7M | ||
| Q2 25 | $2.6B | $690.0M | ||
| Q1 25 | $2.6B | $686.1M | ||
| Q4 24 | $2.5B | $690.5M | ||
| Q3 24 | $2.5B | $712.7M |
| Q2 26 | $3.2B | — | ||
| Q1 26 | $3.2B | $1.1B | ||
| Q4 25 | $3.2B | $1.1B | ||
| Q3 25 | $3.2B | $1.2B | ||
| Q2 25 | $3.2B | $1.1B | ||
| Q1 25 | $3.2B | $1.1B | ||
| Q4 24 | $3.2B | $1.1B | ||
| Q3 24 | $3.1B | $1.1B |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | — | 0.01× | ||
| Q3 24 | — | 0.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $147.3M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 1.55× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $147.3M | — | ||
| Q1 26 | $54.8M | — | ||
| Q4 25 | $54.8M | $-1.9M | ||
| Q3 25 | $472.2M | $22.0M | ||
| Q2 25 | $67.7M | $34.8M | ||
| Q1 25 | $174.9M | $-38.9M | ||
| Q4 24 | $106.8M | $13.9M | ||
| Q3 24 | $327.3M | $-15.3M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $50.2M | $-37.2M | ||
| Q3 25 | $435.9M | $-6.4M | ||
| Q2 25 | $61.3M | $17.0M | ||
| Q1 25 | $168.0M | $-66.4M | ||
| Q4 24 | $100.0M | $-1.3M | ||
| Q3 24 | $297.2M | $-32.9M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 14.5% | -13.9% | ||
| Q3 25 | 142.0% | -2.1% | ||
| Q2 25 | 19.4% | 5.6% | ||
| Q1 25 | 45.5% | -23.7% | ||
| Q4 24 | 28.0% | -0.5% | ||
| Q3 24 | 97.5% | -14.5% |
| Q2 26 | — | — | ||
| Q1 26 | — | 0.0% | ||
| Q4 25 | 1.3% | 13.2% | ||
| Q3 25 | 11.8% | 9.3% | ||
| Q2 25 | 2.0% | 5.8% | ||
| Q1 25 | 1.9% | 9.8% | ||
| Q4 24 | 1.9% | 6.3% | ||
| Q3 24 | 9.8% | 7.7% |
| Q2 26 | 1.55× | — | ||
| Q1 26 | 1.03× | — | ||
| Q4 25 | 1.03× | — | ||
| Q3 25 | 9.57× | 2.72× | ||
| Q2 25 | 1.47× | 9.41× | ||
| Q1 25 | 1.91× | -29.92× | ||
| Q4 24 | 1.57× | — | ||
| Q3 24 | 5.59× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DLB
| Licensing | $372.2M | 94% |
| Products and services | $23.4M | 6% |
MTUS
Segment breakdown not available.
